[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sarcoidosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sarcoidosis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,25,0,[8,45,74,114,149,179,201,222,248,283,324,373,399,422,443,467,488,515,539,561,597,624,654,681,701],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100331323","phase-3-cardiac-sarcoidosis-randomized-trial-100331323",false,"NCT03593759","Cardiac Sarcoidosis Randomized Trial","Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial","CHASM-CS-RCT","Inclusion Criteria:\n\n(i) Cardiac sarcoidosis presenting with one or more of the following clinical findings:\n\n* advanced conduction system disease (defined as Mobitz II AV block or third degree AV block)\n* significant sinus node dysfunction (defined as average HR less than 40bpm when awake and\u002For sustained atrial arrhythmias)\n* non- sustained or sustained ventricular arrhythmia\n* left ventricular dysfunction (LVEF \\\u003C 50%)\n* right ventricular dysfunction (RVEF \\\u003C 40%)\n\nAND\n\n(ii) No alternative explanation for clinical features\n\nAND\n\n(iii) Nuclear Imaging within six-months of enrollment consisting of FDG-PET scan with FDG uptake suggestive of active CS and myocardial perfusion imaging\n\nAND ONE OR BOTH OF FOLLOWING\n\n(iv) Positive biopsy for Sarcoid (either EMB or extra-cardiac)\n\n(v) CT Chest showing features consistent with pulmonary sarcoidosis and\u002For mediastinal and\u002For hilar lymphadenopathy\n\nExclusion Criteria:\n\n1. Current or recent (within two months) non-topical treatment for sarcoidosis\n2. Current Oral\u002FIV treatment of duration greater than 5 days\n3. Currently taking Methotrexate or Prednisone for another health condition\n4. Intolerance or contra-indication to Methotrexate or Prednisone\n5. Patient does not meet all of the above listed inclusion criteria\n6. Patient is unable or unwilling to provide informed consent\n7. Patient is included in another randomized clinical trial\n8. Patient has a contraindication to PET imaging or is unlikely to tolerate due to severe claustrophobia\n9. Pregnancy (all women of child bearing age and potential will have a negative BHCG test before enrollment)\n10. Breastfeeding\n11. Women of childbearing age who refuse to use a highly effective and medically acceptable form of contraception throughout the study\n12. Patients for whom the investigator believes that the trial is not in the interest of the patient","ALL","18 Years",{"count":20,"type":21},194,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Prospective randomized controlled trial comparing low dose Prednisone(or Prednisolone)\u002FMethotrexate combination to standard dose Prednisone(or Prednisolone) in patients diagnosed with acute active clinically manifest cardiac sarcoidosis and not yet treated.\n\nThe Investigators hypothesize that low dose Prednisone(or Prednisolone)\u002FMethotrexate combination will be as effective as standard dose Prednisone(or Prednisolone), and result in significantly better quality of life and less toxicity than standard dose Prednisone(or Prednisolone).",[27,28],"Cardiac Sarcoidosis","Sarcoidosis",[27,30,31],"Prednisone (or Prednisolone)","Methotrexate","RECRUITING","2026-06-29",{"date":35,"type":36},"2026-07-02","ACTUAL",{"date":38,"type":36},"2019-01-15",{"date":40,"type":21},"2026-12",{"name":42,"class":43},"Ottawa Heart Institute Research Corporation","OTHER",31,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100092968","a-study-of-the-natural-progression-of-interstitial-lung-disease-ild-100092968","NCT00470327","A Study of the Natural Progression of Interstitial Lung Disease (ILD)","Inclusion Criteria:\n\n* Interstitial lung disease\n\nExclusion Criteria:\n\n* Does not have Interstitial lung disease",true,{"count":53,"type":21},4000,"OBSERVATIONAL","We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data and blood samples from a control group for comparator purposes. In doing so, we will be able to describe the \"phenotypic\" expression of these diseases.",[57,58,28,59],"Interstitial Lung Diseases","Idiopathic Pulmonary Fibrosis","Connective Tissue Disorder",[61,62,28,63],"Interstitial lung diseases","idiopathic pulmonary fibrosis","mRNA and cytokine expression","2026-06-05",{"date":66,"type":36},"2026-06-09",{"date":68,"type":36},"2005-09",{"date":70,"type":21},"2030-12",{"name":72,"class":43},"University of Chicago",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":83,"conditions":84,"keywords":97,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":73},"100598885","eacvi-study-on-multimodality-cardiovascular-imaging-of-inflammatory-cardiovascular-diseases-100598885","NCT07077304","EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases","EACVI-INFLAME","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Ability to provide informed non-opposition\n3. Referred for a CMR and\u002For nuclear imaging exam\n\nAND a suspicion of one of the following ICARDs :\n\n1. Suspected Myocarditis (acute or chronic, and whatever the aetiologies)\n2. Suspected Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA)\n3. Suspected Tako-Tsubo\n4. Suspected Pericarditis (acute or chronic, and whatever the aetiologies)\n5. Suspected Connective tissue disease with cardiovascular involvement:\n\n   * Systemic sclerosis\n   * Systemic lupus erythematosus\n   * Antiphospholipid syndrome\n   * Idiopathic inflammatory myopathies\n   * Rheumatoid arthritis, spondylarthritis\n6. Suspected Vasculitis with cardiovascular involvement:\n\n   * Small-vessel vasculitis (ANCA…)\n   * Large vessel vasculitis (Behcet disease, Takayasu…)\n7. Suspected Inflammatory disease with cardiovascular involvement:\n\n   * Sarcoidosis\n   * Still disease\n\nExclusion Criteria:\n\n1. Inability to provide non-opposition\n2. History of heart transplant",{"count":82,"type":21},5000,"Inflammatory Cardiovascular Diseases and Autoimmune Rheumatic Diseases (ICARDs) encompass cardiovascular involvement in connective tissue diseases, vasculitis, and primary inflammatory cardiac processes affecting all layers of the heart. ICARDs are associated with increased cardiovascular morbidity and mortality, independently of traditional risk factors, via multiple pathophysiological mechanisms.\n\nDiagnosis and prognosis are challenged by the heterogeneity of clinical presentations. Multimodality cardiovascular imaging - including cardiovascular magnetic resonance (CMR), transthoracic echocardiography, and positron emission tomography (PET) - plays a central role in detecting and characterizing inflammatory involvement, and may offer prognostic insights.\n\nGiven the limited data on the diagnostic and prognostic utility of these imaging modalities in ICARDs, the EACVI-INFLAME study aims to assess the prevalence of confirmed cardiovascular involvement in patients with suspected or established ICARDs undergoing CMR and\u002For cardiac PET in a multicentric international cohort.",[85,86,87,88,89,90,91,92,93,94,28,95,96],"Myocarditis","ANCA Associated Vasculitis","Pericarditis","Systemic Sclerosis","Systemic Lupus Erythematosus","Idiopathic Inflammatory Myopathies","Rheumatoid Arthritis","Spondylarthritis","Behcet Disease","Takayasu Arteritis","Still Disease","Tako Tsubo Cardiomyopathy",[98,99,100,101,102,103,104,105],"Cardiovascular disease","Auto-immune disease","Auto-inflammatory disease","Rheumatic disease","CMR","PET","multimodality imaging","ICARD","2026-06-03",{"date":64,"type":36},{"date":109,"type":36},"2025-11-19",{"date":111,"type":21},"2028-10-30",{"name":113,"class":43},"Assistance Publique - Hôpitaux de Paris",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":51,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":148},"100289553","mayo-avc-registry-and-biobank-100289553","NCT03049254","Mayo AVC Registry and Biobank","Identification of Novel Genetic Variants and Biomarkers of Disease Progression in Arrhythmogenic Cardiomyopathy","Inclusion Criteria:\n\n* Patients with a diagnosis of a non-MI SCA who survived\n* Patients with a non-MI SCD\n* Patient with a SCA associated with seizures, epilepsy, syncope, drowning and near-drowning, where a cardiomyopathy is suspected\n* Family member of a patient diagnosed with primary cardiomyopathy (including HCM, idiopathic DCM, AVC)\n\nExclusion Criteria:\n\n* Patients with a clear, unambiguous known cause of SCA or SCD such as myocardial infarction or heart failure secondary to ischemic heart disease\n* Significant coronary artery disease (Epicardial coronary artery stenosis \\>50%) which can explain degree of LV dysfunction\n* Those unwilling to provide written consent or assent",{"count":122,"type":21},1000,"Arrhythmogenic ventricular cardiomyopathy (AVC) is a genetic condition which affects the heart and can lead to heart failure and rhythm problems, of which, sudden cardiac arrest or death is the most tragic and dangerous. Diagnosis and screening of blood-relatives is very difficult as the disease process can be subtle, but sufficient enough, so that the first event is sudden death.\n\nThe Mayo Clinic AVC Registry is a collaboration between Mayo Clinic, Rochester, USA and Papworth Hospital, Cambridge University Hospitals, Cambridge, UK. The investigators aim to enroll patients with a history of AVC or sudden cardiac death which may be due to AVC, from the US and UK. Family members who are blood-relatives will also be invited, including those who do not have the condition. Data collected include symptoms, ECG, echocardiographic, MRI, Holter, loop recorder, biopsies, exercise stress testing, blood, buccal and saliva samples.\n\nObjectives of the study:\n\n1. Discover new genes or altered genes (variants) which cause AVC\n2. Identify biomarkers which predict (2a) disease onset, (2b) disease progression, (2c) and the likelihood of arrhythmia (ventricular, supra-ventricular and atrial fibrillation)\n3. Correlate genotype with phenotype in confirmed cases of AVC followed longitudinally using clinical, electrocardiographic and imaging data.\n4. Characterize desmosomal changes in buccal mucosal cells with genotype and validate with gold-standard endomyocardial biopsies",[125,126,127,128,129,130,131,132,133,134,28,135,27,85,136,137,138],"Arrhythmogenic Right Ventricular Cardiomyopathy","Cardiomyopathies","Heart Diseases","Cardiovascular Diseases","Sudden Cardiac Arrest","Sudden Cardiac Death","Arrhythmogenic Right Ventricular Dysplasia","Arrhythmogenic Ventricular Cardiomyopathy","Familial Dilated Cardiomyopathy","Cardiovascular Abnormalities","Cardiac Arrhythmia","Inflammatory Cardiomyopathy","Ventricular Tachycardia","Right Ventricular Outflow Tract Ventricular Tachycardia","2026-04-22",{"date":141,"type":36},"2026-04-27",{"date":143,"type":36},"2018-02-09",{"date":145,"type":21},"2027-03",{"name":147,"class":43},"Mayo Clinic",2,{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":22,"phases":158,"briefSummary":160,"conditions":161,"keywords":166,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":73},"100598628","virtual-patient-groups-for-sarcoidosis-associated-fatigue-100598628","NCT07073963","Virtual Patient Groups for Sarcoidosis Associated Fatigue","SupportSarc","Inclusion Criteria:\n\n* Self reported diagnosis of sarcoidosis\n* Fatigue defined as FAS score ≥ 22\n* Age ≥ 18 years old\n* Ability to speak and read English\n* Access to internet\n* Capacity to consent\n\nExclusion Criteria:\n\n* Current daily meditation practice\n* Prior history of engaging in formal mindfulness-based interventions including: MBSR, MBCT, Acceptance and Commitment therapy, Dialectical Behavior Therapy\n* Any condition that would prevent being a suitable candidate for the group intervention (as determined by screening interview) including suicidal ideation.\n* Lack of access to any form of online video access",{"count":157,"type":21},100,[159],"NA","This research study is testing whether Mindfulness-Based Stress Reduction (MBSR) can help reduce fatigue in people with sarcoidosis. The study will also look at whether MBSR can improve symptoms of anxiety and depression.\n\nParticipants will be placed into one of two groups:\n\n* One group will take part in an 8-week virtual MBSR program, attend weekly online sessions, keep a daily mindfulness journal, and complete surveys about fatigue, anxiety, and depression.\n* The other group will join a virtual support group once a month for 5 months and complete the same surveys.\n\nThe goal is to see which approach is more helpful for improving fatigue and mental well-being in people with sarcoidosis.",[28,162,163,164,165],"Fatigue","Depression","Anxiety","Mental Health",[167,168,169],"mindfulness","support group","virtual","2026-04-21",{"date":172,"type":36},"2026-04-24",{"date":174,"type":36},"2026-02-26",{"date":176,"type":21},"2028-03-01",{"name":178,"class":43},"The Cleveland Clinic",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":22,"phases":187,"briefSummary":188,"conditions":189,"keywords":190,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":73},"100631297","corticosteroid-tapering-in-sarcoidosis-100631297","NCT07498842","Corticosteroid Tapering in Sarcoidosis","SARC-Taper","Inclusion Criteria:\n\n* Confirmed sarcoidosis by: (a) Histological diagnosis and\u002For (b) Multidisciplinary Team (MDT) diagnosis\n* Prednisolone 5-10mg\u002Fday for \\> 6 months\n* Clinically stable disease for \\> 6 months (no flares or dose escalation)\n* On or off second-line agent\n* \\> 18 years old\n* Written informed consent provided\n\nExclusion Criteria:\n\n* Cardiac or neurosarcoidosis\n* Advanced pulmonary sarcoidosis defined as either: (a) composite physiological index (CPI) \\> 40 (b) pulmonary hypertension\n* Active sarcoidosis flare or dose escalation in the past 6 months\n* Known adrenal insufficiency\n* Pregnancy or breastfeeding\n* Previous or current infliximab use",{"count":157,"type":21},[159],"Sarcoidosis is an inflammatory condition affecting many different parts of the body but most commonly the lungs. It is not known what causes sarcoidosis. In some patients no treatment is needed but in other patients long term treatment may be required.\n\nOne of the main medications used to manage this condition is corticosteroids. This medication has been shown to be very effective at reducing inflammation in this condition and many patients often remain on it for months to years.\n\nUnfortunately, there are many negative long-term side effects of corticosteroid use. This includes an increased risk of developing diabetes, reduced bone density, weight gain, high blood pressure and low muscle mass. Currently there are no guidelines for how steroids should be weaned in patients who have stable sarcoidosis.\n\nThe investigators aim to undertake a study at the Royal Brompton Hospital which will be assessing two different steroid tapering regimens which will be allocated to participants in a randomised manner. This will be the first study to directly evaluate different steroid weaning regimens in sarcoidosis patients.\n\nThe main aim of this study is to determine how many participants can reduce their prednisolone dose to less than 50% from their baseline dose. Additionally, the investigators will be recording how many participants require an increase in dose or an additional medication whilst on the prednisolone weaning regimen. The investigators will also see the tolerability of steroid withdrawal and assess for any symptoms of steroid withdrawal. In a small subset of participants the investigators will assess for any changes in body composition and muscle strength using bioelectrical impedance analysis and isometric muscle testing.",[28],[191],"corticosteroid tapering","2026-03-23",{"date":194,"type":36},"2026-03-27",{"date":196,"type":36},"2026-03-19",{"date":198,"type":21},"2027-10-18",{"name":200,"class":43},"Royal Brompton & Harefield NHS Foundation Trust",{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":73},"100560389","immunological-mechanisms-in-sarcoidosis-100560389","NCT06576505","Immunological Mechanisms in Sarcoidosis","Immunologiska Mekanismer Vid Sarkoidos","Inclusion Criteria:\n\n* Suspicion of sarcoidosis\n* Swedish speaking\n* Able to understand and approve of study protocol\n* No contraindications for planned interventions\n* For inclusion of healthy controls they need to be healthy and the same criteria as listed above for patients.\n\nExclusion Criteria:\n\n* No suspicion of sarcoidosis\n* Not Swedish-speaking\n* Not able to understand study protocol\n* Not approving of study protocol\n* Contraindications for planned interventions","90 Years",{"count":82,"type":21},"There is no cure for the inflammatory disease sarcoidosis. Virtually any part of the body can be affected but most often the lungs and lymph nodes. Outcomes after diagnosis vary widely among sarcoidosis patients, with some experiencing resolving disease and others developing chronic disease and lung fibrosis. Cardiac sarcoidosis can lead to life threatening arrythmias and calcium metabolism disturbances can lead to renal impairment.\n\nTreatment with different forms of immunosuppressants are usually tried to dampen symptoms but are not effective in all patients. Furthermore, the disease usually flares up after cessation of treatment. The variability in diseae course and treatment response is thought, at least to some degree, to be explained by individual differences in genetics, immune cells and signaling pathways. But existing evidence is limited. In other inflammatory diseases the gut microbiome is of importance for disease course but its role in sarcoidosis has not been clarified.\n\nIn this prospective project the investigators will study genes, inflammatory cells and signaling molecules in the lung, upper airways and blood, and to some extent microbes, also in faeces. Healthy volunteers will be included for comparative studies. Most samples will be taken during normal diagnostic work-up and follow-up of patients with\u002Fwith suspected sarcoidosis. The findings will be correlated to disease course and effects of different treatments. By linking to national health data and demographic registries, comorbidities and environmental factors will be correlated to data.\n\nBy this, the investigators hope to improve understanding of which genes, cells and signaling molecules that are of importance for resolving vs non-resolving disease and why some patients respond to a certain treatment and others don´t. The overall goal is to assess and predict sarcoidosis outcomes. We hypothesize that blood-based biomarkers including those taken during routine care as well as novel cell, signaling molecules and genetic markers, in combination with clinical characteristics can be used to predict outcomes, also treatment response, in sarcoidosis. The results can lead to tailored treatment and individual follow-up for each patient with sarcoidosis.",[28],"2026-03-05",{"date":214,"type":36},"2026-03-06",{"date":216,"type":36},"2024-07-07",{"date":218,"type":21},"2034-12-31",{"name":220,"class":221},"Region Stockholm","OTHER_GOV",{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":231,"conditions":232,"keywords":234,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":73},"100509685","moma-signature-during-granulomatosis-100509685","NCT05916638","MoMa Signature During Granulomatosis","Role of Monocytes (Mo) and Macrophages (Ma) in Sarcoidosis and in Tuberculosis","MOSAR","Inclusion criteria:\n\n1. Male and female \\> 18 years old\n2. Diagnosis of sarcoidosis and of tuberculosis\n3. Affiliated to medical insurance\n\nExclusion criteria:\n\n1. HIV infection\n2. pregnant or breastfeeding woman\n3. Patient under legal protection, guardianship or curators\n4. Absence of signed consent\" Secondary exclusion criteria Other causes of granulomatosis ultimately identified as sarcoidosis or tuberculosis",{"count":157,"type":21},"Sarcoidosis is a systemic inflammatory disease characterized by unspecific granuloma formation. Our hypothesis is that granuloma formation and maintenance mainly relies on the overactivation of monocytes (Mo) and macrophages (Ma). To this end, the study aims (i) to define MoMa systemic signature in sarcoidosis, (ii) to characterize this signature in situ on tissue samples, and (iii) to identify causative factors that participate to the MoMa chronic overactivation. Thus, a cohort of sarcoidosis patients will be compared with tuberculosis patients. The MoMa systemic signature will be defined on whole blood (TruCulture model) and then in situ through different methods (multi-parameter spectral flow cytometry, RNA-seq, Luminex, imaging mass cytometry). The epigenome of monocytes will be studied thanks to CUT\\&Tag. The MoMa systemic signature will be defined ex vivo at different time points during the course of the disease with phenotypic, transcriptomic, cytokine and functional approaches. The previously identified signature will be studied in situ and completed by the characterization of granuloma architecture and microenvironmental interactions, which could be modulated by epigenetic modifications. Hence, the epigenome of monocytes will be analyzed in two groups (sarcoidosis and tuberculosis). These results would allow to better understand sarcoidosis physiopathology and, in fine, may raise new therapeutic strategies. Finally, the study could challenge the dogma on innate immunity\u002Fauto-inflammation versus adaptive immunity\u002Fauto-immunity\u002Fmemory.",[28,233],"Tuberculosis",[235,236,237,238,239],"tuberculosis","sarcoidosis","granuloma","monocytes","macrophages","2026-02-27",{"date":242,"type":36},"2026-03-03",{"date":244,"type":36},"2024-01-15",{"date":246,"type":21},"2030-01",{"name":113,"class":43},{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":254,"enrollmentInfo":255,"targetDuration":256,"studyType":54,"phases":4,"briefSummary":257,"conditions":258,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":73},"100393366","rheumatology-patient-registry-and-biorepository-100393366","NCT04402086","Rheumatology Patient Registry and Biorepository","Inclusion Criteria for Rheumatology Patients:\n\n* Patients ≥18 years old with a diagnosis of a rheumatic autoimmune disease including, but not limited to: adult onset Still's disease, ankylosing spondylitis, antiphospholipid syndrome, Behcet's disease, dermatomyositis, giant cell arteritis, mixed connective tissue disease, polymyalgia rheumatica, polymyositis, psoriatic arthritis, reactive arthritis, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, systemic lupus erythematosus, undifferentiated connective tissue disease and vasculitis.\n* Receiving clinical care at Yale Rheumatology clinics\n\nExclusion Criteria for Rheumatology Patients:\n\n* Unable to provide informed consent\n* No patients will be excluded based on gender or ethnicity or pregnancy status.\n* Women who are currently pregnant will need to wait to donate a skin biopsy until after they deliver.\n* Patients allergic to lidocaine or epinephrine or have a history of impaired wound healing will not be able to donate a skin biopsy.\n\nInclusion Criteria for Healthy Volunteers:\n\n* Age ≥ 18 years old\n* No chronic skin conditions\n* No diagnosis of a rheumatic autoimmune disease (e.g., lupus, rheumatoid arthritis)\n* Normal BMI\n\nExclusion Criteria for Healthy Volunteers:\n\n* Unable to provide informed consent.\n* Currently pregnant or nursing unless the study goal is to study pregnant or nursing woman.\n* Allergies to lidocaine or epinephrine (skin biopsies).\n* A history of impaired wound healing (skin biopsies).","99 Years",{"count":82,"type":21},"10 Years","To facilitate clinical, basic science, and translational research projects involving the study of rheumatic diseases.",[259,260,261,262,263,264,89,93,265,266,267,268,269,270,91,28,88,271,272,273],"Rheumatic Diseases","Adult Onset Still Disease","Ankylosing Spondylitis","Psoriatic Arthritis","Reactive Arthritis","Antiphospholipid Syndrome","Dermatomyositis","Polymyositis","Giant Cell Arteritis","Lyme Disease","Mixed Connective Tissue Disease","Polymyalgia Rheumatica","Scleroderma","Sjogren's Syndrome","Undifferentiated Connective Tissue Diseases","2026-02-11",{"date":276,"type":36},"2026-02-13",{"date":278,"type":36},"2020-08-04",{"date":280,"type":21},"2030-06-01",{"name":282,"class":43},"Yale University",{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":287,"acronym":288,"eligibilityCriteria":289,"healthyVolunteers":51,"sex":17,"minAge":4,"maxAge":290,"enrollmentInfo":291,"targetDuration":4,"studyType":22,"phases":293,"briefSummary":294,"conditions":295,"keywords":300,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":73},"100622536","immune-cells-role-in-lung-cancer-and-their-use-in-anticancer-immunotherapies-and-inflammatory-lung-disease-100622536","NCT07384897","Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung Disease","IMMUNOPUMON2","Inclusion Criteria:\n\n* Diagnosis of lung cancer\n* Presence of precancerous lung lesions\n* Patients with a chronic inflammatory lung disease (sarcoidosis or chronic obstructive pulmonary disease \\[COPD\\]) prior to any treatment\n* Control group: individuals without known lung disease\n* Children and adolescents weighing ≥ 10 kg with genetically confirmed chronic granulomatous disease (CGD)\n* Adults scheduled to undergo orthopedic surgery during which a bone marrow sample will be collected\n\nExclusion Criteria:\n\n* Systemic corticosteroid therapy \\> 10 mg\u002Fday prednisone (or equivalent)\n* Acute infection at the time of inclusion\n* Refusal or inability to provide informed consent (or assent, when applicable)\n* Chronic inflammatory lung disease currently treated with immunosuppressive therapy","80 Years",{"count":292,"type":21},425,[159],"This study aims to better understand the role of immune system cells in lung diseases such as lung cancer, sarcoidosis, and chronic obstructive pulmonary disease (COPD).\n\nThe investigators are studying how these immune cells can sometimes help the body defend itself, but in other cases may contribute to cancer growth or long-term lung inflammation.\n\nAlthough recent treatments like immunotherapy have improved cancer care, only a small proportion of patients currently benefit from these therapies. One goal of this research is to understand why some patients do not respond or develop resistance to treatment.\n\nThe knowledge gained from this study may help researchers develop more effective and personalized treatments for people with lung diseases in the future.",[296,28,297,298,299],"Lung Cancer (Diagnosis)","Chronic Obstructive Pulmonary Disease","Immunotherapy Resistance","Immune Dysregulation",[301,302,28,297,303,304,305,299,306,298,307,308,309,310,311,312,313,314],"lung cancer","Non-Small Cell Lung Cancer","COPD","Immune Cells","Tumor Microenvironment","Immunotherapy","Immune Profiling","Myeloid Cells","Neutrophils","Dendritic Cells","Inflammation","Chronic Inflammation","Immune suppression","Emergency myelopoiesis","2026-01-26",{"date":317,"type":36},"2026-02-03",{"date":319,"type":36},"2025-02-17",{"date":321,"type":21},"2032-02-17",{"name":323,"class":43},"Université Catholique de Louvain",{"id":325,"slug":326,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":331,"targetDuration":256,"studyType":54,"phases":4,"briefSummary":333,"conditions":334,"keywords":360,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":371,"locationsCount":73},"100560175","institutional-registry-of-rare-diseases-100560175","NCT06573723","Institutional Registry of Rare Diseases","Institutional Registries of Rare Diseases at Hospital Italiano de Buenos Aires (HIBA)","Inclusion Criteria:\n\n* Clinical and\u002For molecular diagnosis of any of the following rare diseases: Amyloidosis, Sarcoidosis, Phacomatosis, Pheochromocytoma, Paraganglioma, Von Hippel-Lindau Disease, Immunoglobulin G4-Related Disease, Demyelinating Diseases, Inborn Errors of Metabolism, Eosinophilic Gastrointestinal Disorders, Hypertrophic Cardiomyopathy, Gaucher Disease, Congenital Adrenal Hyperplasia, Hereditary Angioedema, Pulmonary Hypertension, Wilson Disease, Vascular Anomalies, Mastocytosis, Multiple Endocrine Neoplasia, Inflammatory Bowel Diseases, Prader-Willi Syndrome, Hirschsprung Disease, or Cushing Syndrome.\n* Must be followed at Hospital Italiano de Buenos Aires.\n\nExclusion Criteria:\n\n\\- Refusal to participate in the study or in the informed consent process.",{"count":332,"type":21},380,"The goal of this observational study is to create a single macro registry system with data collection on common clinical features, grouping the different rare diseases (RD).\n\nMoreover, the specific goals are to generate an alert system for possible cases of RD with data from the electronic medical record, to describe the occurrence of RD in the evaluated population, to characterize the population, to describe patterns of diagnosis and treatment of RD present at the time, and to explore patient-reported outcomes.",[335,336,28,337,338,339,340,341,342,343,344,345,346,347,348,349,350,351,352,353,354,355,356,357,358,359],"Rare Diseases","Amyloidosis","Phacomatosis","Pheochromocytoma","Paraganglioma","Von Hippel-Lindau Disease","Immunoglobulin G4-Related Disease","Demyelinating Diseases","Inborn Errors of Metabolism","Eosinophilic Gastrointestinal Disorders","Hypertrophic Cardiomyopathy","Gaucher Disease","Congenital Adrenal Hyperplasia","Hereditary Angioedema","Pulmonary Hypertension","Wilson Disease","Vascular Anomalies","Mastocytosis","Multiple Endocrine Neoplasia","Inflammatory Bowel Diseases","Prader-Willi Syndrome","Hirschsprung Disease","Cushing Syndrome","HHT","Hemorrhagic Hereditary Telangiectasia",[361,362,236,337,363,364,340,341,342,343,344,345,346,347,348,349,350,351,352,353,354,355,356,357,359],"rare diseases","amyloidosis","pheochromocytoma","paraganglioma","2026-01-12",{"date":367,"type":36},"2026-01-14",{"date":369,"type":36},"2024-07-01",{"date":218,"type":21},{"name":372,"class":43},"Hospital Italiano de Buenos Aires",{"id":374,"slug":375,"hasResults":11,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":379,"eligibilityCriteria":380,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":22,"phases":383,"briefSummary":384,"conditions":385,"keywords":389,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":148},"100351663","cell-free-dna-in-cardiac-sarcoidosis-100351663","NCT03858777","Cell Free DNA in Cardiac Sarcoidosis","Cardiomyocyte Specific Cell Free DNA as a Marker of Cardiac Sarcoidosis","cfDNA in CS","1. Sarcoidosis patients without evidence of active myocarditis:\n\n   * Inclusion:\n\n     * Diagnosis of sarcoidosis based on the ATS\u002FERS criteria.\n     * Normal 12 lead ECG within the past one year.\n     * Non-smoker.\n     * No immunosuppressive therapy for at least one year.\n   * Exclusion:\n\n     * Known cardiac disease.\n     * Active smoker.\n     * On immunosuppressive therapy.\n2. Sarcoidosis patients with evidence of active myocarditis:\n\n   * Inclusion:\n\n     * Diagnosis of sarcoidosis based on the ATS\u002FERS criteria.\n     * Evidence of active myocarditis based on recent cMRI or cFDG-PET.\n     * Non-smoker.\n   * Exclusion:\n\n     * Known cardiac disease other than sarcoidosis.\n     * Active smoker.\n     * On immunosuppressive therapy.\n3. Acute ST elevation myocardial infarction (STEMI):\n\n   * Inclusion:\n\n     * Diagnosis STEMI based on 1mm ST elevation in 2 or more contiguous leads.\n     * Symptom onset within 12 hours.\n     * Undergoing cardiac intervention for acute coronary syndrome.\n     * Able to consent for blood draw.\n   * Exclusion:\n\n     * Active smoker.\n     * Hemodynamically unstable.\n4. Healthy controls:\n\n   * Inclusion:\n\n     * No known cardiac disease.\n     * No known cardiovascular risk factors: hypertension, diabetes.\n     * Non-smoker.",{"count":382,"type":21},120,[159],"Sarcoidosis is a multisystem granulomatous disease of unknown cause that can affect any organ in the body, including the heart. Granulomatous myocarditis can lead to ventricular dysfunction and ventricular arrhythmias causing significant morbidity and mortality. Immunosuppressive therapy (IST) has been shown to reverse active myocarditis and preserve left ventricular (LV) function and in some cases improve LV function. In addition, IST can suppress arrhythmias that develop due to active myocarditis and prevent the formation of scar.\n\nThe potential role of cardiac biomarkers, including brain natriuretic peptide (BNP), atrial natriuretic peptide (ANP), and cardiac troponins, in detecting active myocarditis is limited and studies have been disappointing. At present, there are no biomarkers to detect active myocarditis and the use of advanced imaging modalities (FDG-PET) for assessing and monitoring active myocarditis is not feasible or practical and is associate with high radiation exposure. As such, a biomarker that is reflective of active myocarditis and that is cardiac specific will assist physicians in assessing the presence of active myocarditis to guide therapeutic decisions and to assess response to therapy which can limit further cardiac damage.\n\nCell free DNA (cfDNA) are fragments of genomic DNA that are released into the circulation from dying or damaged cells. It is a powerful diagnostic tool in cancer, transplant rejection and fetal medicine especially when the genomic source differs from the host. A novel technique that relies on tissue unique CpG methylation patterns can identify the tissue source of cell free DNA in an individual reflecting potential tissue injury. We will be conducting a pilot study to explore the utility of this diagnostic tool to identify granulomatous myocarditis in patients with sarcoidosis.",[386,28,387,388],"Sarcoidosis With Myocarditis","Healthy","ST Elevation Myocardial Infarction",[236],"2026-01-07",{"date":392,"type":36},"2026-01-09",{"date":394,"type":36},"2019-05-01",{"date":396,"type":21},"2028-06-30",{"name":398,"class":43},"Nabeel Hamzeh",{"id":400,"slug":401,"hasResults":11,"nctId":402,"briefTitle":403,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":11,"sex":17,"minAge":405,"maxAge":4,"enrollmentInfo":406,"targetDuration":4,"studyType":22,"phases":408,"briefSummary":410,"conditions":411,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":73},"100333455","phase-4-vitamin-d-homeostasis-in-sarcoidosis-100333455","NCT03621553","Vitamin D Homeostasis in Sarcoidosis","Inclusion Criteria:\n\n* Stable medical condition defined as no hospitalization or emergency room visit in the previous 3 months\n* No evidence of active pulmonary or systemic infection\n* No other active inflammatory disease,\n* No active malignancy.\n* Normal serum ionized calcium level\n\nExclusion Criteria:\n\n* Hospitalization or emergency room visit in the previous 3 months\n* Evidence of active pulmonary or systemic infection\n* Evidence of active other inflammatory disease\n* Evidence of active malignancy\n* Elevated serum ionized calcium level","21 Years",{"count":407,"type":21},90,[409],"PHASE4","This study evaluates the relationship between vitamin-D status and severity of sarcoidosis, and the effects of vitamin-D repletion in vitamin-D insufficient patients with sarcoidosis. Half the patients with sarcoidosis who are vitamin-D insufficient will receive standard vitamin-D supplementation via standard regimen while the other half will receive a placebo. Sarcoidosis patients who are vitamin-D sufficient will also act as controls.",[28,412],"Vitamin D Insufficiency","2025-12-30",{"date":415,"type":36},"2026-01-02",{"date":417,"type":36},"2010-07-01",{"date":419,"type":21},"2026-12-30",{"name":421,"class":43},"University of Texas Southwestern Medical Center",{"id":423,"slug":424,"hasResults":11,"nctId":425,"briefTitle":426,"officialTitle":426,"acronym":4,"eligibilityCriteria":427,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":428,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":430,"conditions":431,"keywords":433,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":73},"100452436","full-field-optical-coherence-tomography-ffoct-for-evaluation-of-bronchoscopic-small-biopsy-specimens-100452436","NCT05171478","Full-Field Optical Coherence Tomography (FFOCT) for Evaluation of Bronchoscopic Small Biopsy Specimens","Inclusion Criteria:\n\n* Inpatients or outpatients greater than or equal to 18 years old\n* Capable of providing informed consent\n* Undergoing bronchoscopy for diagnosis or staging per standard of care\n* Collection of small biopsy samples by EBUS or conventional transbronchial needle aspiration (TBNA) or transbronchial biopsy for purposes outside of the research study\n\nExclusion Criteria:\n\n* Standard contraindications bronchoscopy including bleeding disorders, antiplatelet or anticoagulant usage, severe respiratory failure, and clinical instability\n* Pregnancy",{"count":429,"type":21},20,"This study sets out to register imaging of small biopsy specimens obtained during bronchoscopy using full-field optical coherence tomography against standard histologic evaluation.",[432,28],"Lung Cancer",[301],"2025-12-09",{"date":436,"type":36},"2025-12-17",{"date":438,"type":36},"2021-12-09",{"date":440,"type":21},"2026-12-08",{"name":442,"class":43},"Johns Hopkins University",{"id":444,"slug":445,"hasResults":11,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":449,"eligibilityCriteria":450,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":451,"targetDuration":256,"studyType":54,"phases":4,"briefSummary":452,"conditions":453,"keywords":457,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":465,"locationsCount":73},"100469443","interstitial-lung-disease-research-unit-biobank-100469443","NCT05392881","Interstitial Lung Disease Research Unit Biobank","University of Kansas Medical Center Interstitial Lung Disease Research Unit (ILDRU) Biobank","ILDRU","Inclusion Criteria:\n\n1. The participant is a patient at TUKHS or has agreed to participate in a study approved by the KUMC Human Research Protection Program (HRPP)\n2. The participant is being followed for the presence of autoimmune disease, ILD or other rare lung diseases at TUKHS.\n3. The participant is ≥ 18 years of age.\n4. The participant has signed an approved consent for this study (living patients only)",{"count":122,"type":21},"Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.",[454,28,58,455,456],"Interstitial Lung Disease","Pulmonary Fibrosis","Hypersensitivity Pneumonitis",[454,28,58,455,456],"2025-09-16",{"date":460,"type":36},"2025-09-22",{"date":462,"type":36},"2021-08-09",{"date":464,"type":21},"2032-03-01",{"name":466,"class":43},"University of Kansas Medical Center",{"id":468,"slug":469,"hasResults":11,"nctId":470,"briefTitle":471,"officialTitle":471,"acronym":4,"eligibilityCriteria":472,"healthyVolunteers":51,"sex":17,"minAge":473,"maxAge":4,"enrollmentInfo":474,"targetDuration":476,"studyType":54,"phases":4,"briefSummary":477,"conditions":478,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":479,"lastUpdatePostDateStruct":480,"startDateStruct":482,"completionDateStruct":484,"leadSponsor":486,"locationsCount":73},"100534096","foundation-for-sarcoidosis-research-advanced-cures-registry-fsr-sarc-registry-100534096","NCT06234384","Foundation for Sarcoidosis Research Advanced Cures Registry (FSR-SARC Registry)","Inclusion Criteria:\n\n1. English speaking\n2. Consent\n3. Sarcoidosi diagnosis -\n\nExclusion Criteria:\n\nNONE","7 Years",{"count":475,"type":21},6833,"1 Year","The goal of the study is to create a longitudinal record of patient reported outcomes for people living with sarcoidosis that maintains privacy. Patients report on the following: demographics, disease symptoms, diagnostic journey, provider experience, disease treatment, and burden of disease. Patients can also link their Electronic Health Records (EHR). The goal is to create a natural history of sarcoidosis, support research, and better understand the needs of the sarcoidosis community.",[28],"2025-09-15",{"date":481,"type":36},"2025-09-19",{"date":483,"type":36},"2013-07",{"date":485,"type":21},"2033-07",{"name":487,"class":43},"Foundation for Sarcoidosis Research",{"id":489,"slug":490,"hasResults":11,"nctId":491,"briefTitle":492,"officialTitle":493,"acronym":4,"eligibilityCriteria":494,"healthyVolunteers":51,"sex":17,"minAge":495,"maxAge":496,"enrollmentInfo":497,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":499,"conditions":500,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":513,"locationsCount":73},"100597996","quantification--classification-of-inflammatory-cells-in-uveitis-using-oct-100597996","NCT07065747","Quantification & Classification of Inflammatory Cells in Uveitis Using OCT","Objective Grading of Intraocular Inflammation in Uveitis Using Optical Coherence Tomography","Inclusion Criteria:\n\n1. Uveitis Group: Eyes with active intraocular inflammation and a clinical diagnose of spondyloarthritis\u002FHLA-B27 associated anterior uveitis, Juvenile Idiopathic Arthritis (JIA) associated chronic anterior uveitis, Herpes Simplex Virus (HSV) anterior uveitis, Birdshot chorioretinitis, Behcet disease uveitis, sarcoidosis associated uveitis, uveitis of any additional type, or uveitis masquerade.\n2. Posterior Vitreous Detachment Group: Eyes with vitreous floaters and posterior vitreous detachment (PVD).\n3. Healthy\u002FControl Group: Healthy eyes with no history of uveitis, PVD, or previous eye surgery.\n\nExclusion Criteria:\n\n1. Inability to give informed consent.\n2. Inability to maintain stable fixation for OCT imaging.\n3. Inability to commit to required visits to complete the study.\n4. Pregnancy and breastfeeding.","5 Years","85 Years",{"count":498,"type":21},125,"The goal of this study is to determine if it's possible to use a high resolution imaging device called optical coherence tomography (OCT) to develop an unbiased, standard method of counting and categorizing the various types of cells and proteins found in an eye condition called anterior uveitis. Anterior uveitis is a type of inflammation in the eye that can be caused by many different diseases of the body.",[501,502,93,503,504,505,28,506],"Anterior Uveitis (AU)","Birdshot Chorioretinitis","Herpes Simplex Virus","Juvenile Idiopathic Arthritis (JIA)","Spondyloarthritis (SA)","Posterior Vitreous Detachment","2025-07-14",{"date":509,"type":36},"2025-07-17",{"date":511,"type":36},"2024-09-01",{"date":40,"type":21},{"name":514,"class":43},"Oregon Health and Science University",{"id":516,"slug":517,"hasResults":11,"nctId":518,"briefTitle":519,"officialTitle":520,"acronym":521,"eligibilityCriteria":522,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":523,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":525,"conditions":526,"keywords":529,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":532,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":148},"100542828","mediastinal-ebus-cryobiopsy-study-in-sweden-100542828","NCT06347939","Mediastinal EBUS Cryobiopsy Study In Sweden","Mediastinal Endobronchial Ultrasound Bronchoscopy Cryobiopsy Study In Sweden","MECRIS","Inclusion Criteria:\n\n* Mediastinal lymphadenopathy with a diameter greater than 1 cm.\n* Indication for assessment and sampling according to clinical praxis\n* Age \\> 18 years\n* Patients consent to participate in the study.\n\nExclusion Criteria:\n\n* Hemodynamically instable patient\n* Myocardial infarction in the last six weeks prior to participating in the study.\n* Life threatening arrythmia\n* Respiratory failure and inadequate blood oxygenation despite oxygen supply.\n* Tracheal obstruction of high grade.\n* High bleeding risk\n* Patient not willing to participate in the study\n* Patient not speaking swedish and needing translator during the procedure",{"count":524,"type":21},200,"This study is a prospective observational non-randomized clinical trial where all the participitants undergo the same procedure and every participitant's samples are compared to each other. The investigators conduct EBUS TBNA and EBUS TBMCB on all the study participants.The cryobiopsy samples are numbered to evaluate the number of biopsies needed to reach a definite diagnosis and to assess the added value of every sample taken from the same participitant. Every participitant's own samples are compared to each other and added value of EBUS TBMCB is defined as the difference in diagnostic yield between the EBUS TBNA alone and the combination of EBUS TBNA with EBUS TBMCB. Diagnostic yield is defined as the efficacy of the investigation module in reaching a definite diagnosis (percentage of cases with a definite diagnosis).\n\nFollow up four weeks after the procedure to assess the risk for postoperative complications.",[527,432,28,528,233],"Mediastinal Lymphadenopathy","Lymphoma",[530,531,28,233,528],"Mediastinal lymphadenopathy","Lung cancer",{"date":509,"type":36},{"date":534,"type":36},"2024-04-01",{"date":536,"type":21},"2028-12-31",{"name":538,"class":43},"Region Skane",{"id":540,"slug":541,"hasResults":11,"nctId":542,"briefTitle":543,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":546,"targetDuration":256,"studyType":54,"phases":4,"briefSummary":548,"conditions":549,"keywords":550,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":555,"completionDateStruct":557,"leadSponsor":559,"locationsCount":73},"100189710","delayed-enhancement-cardiovascular-magnetic-resonance-in-patients-with-sarcoidosis-100189710","NCT01745237","Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis","Detection and Prognostic Significance of Myocardial Damage Visualized by Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis","Inclusion Criteria:\n\n* Biopsy proven sarcoidosis\n* Suspected cardiac sarcoidosis\n\nExclusion Criteria:\n\n* Contraindication to MRI",{"count":547,"type":21},27000,"The primary objective of this study was to determine the ability of cardiac magnetic resonance (CMR) to identify cardiac involvement in patients with sarcoidosis. Patients were to undergo CMR in addition to routine clinical evaluation.",[28],[28,551],"Cardiac Magnetic Resonance","2025-04-10",{"date":554,"type":36},"2025-04-13",{"date":556,"type":36},"2002-09",{"date":558,"type":21},"2032-06",{"name":560,"class":43},"Duke University",{"id":562,"slug":563,"hasResults":11,"nctId":564,"briefTitle":565,"officialTitle":566,"acronym":567,"eligibilityCriteria":568,"healthyVolunteers":51,"sex":569,"minAge":570,"maxAge":4,"enrollmentInfo":571,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":573,"conditions":574,"keywords":585,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":589,"lastUpdatePostDateStruct":590,"startDateStruct":591,"completionDateStruct":593,"leadSponsor":595,"locationsCount":73},"100569575","aylo---autoimmunity-and-loss-of-y-100569575","NCT06696027","AYLo - AutoimmunitY and Loss of y","Investigating the Role of Hematopoietic Mutations and Mosaic Mutation in the Y Chromosome in Autoimmune Rheumatologic Diseases","AYLo","Inclusion Criteria:\n\n* Male\n* \\> 50 years\n* Diagnosis of arthritis (RA, PsA), collagen diseases (SLE, systemic sclerosis, Sjögren's syndrome, mixed connective tissue diseases), vasculitis (eGPA, GPA, MPA, IgG4-related disease, GCA, PMR), sarcoidosis, COPD, ILD or asthma bronchiale confirmed by the treating physician.\n\nExclusion Criteria:\n\n* Female\n* \\\u003C 50 years\n\nInclusion Criteria (Healthy controls):\n\n* Male\n* \\> 50 years\n\nExclusion Criteria (Healthy controls):\n\n* Female\n* \\\u003C 50 years\n* autoimmune, rheumatological diease\n* pulmonary precondition","MALE","50 Years",{"count":572,"type":21},500,"The AYLo study (AutoimmunitY and Loss of y - Investigating the Role of Hematopoietic Mutations and Mosaic Mutation in the Y Chromosome in Autoimmune Rheumatologic Diseases) aims to systematically investigate hematopoietic mutations, such as hematopoietic (mosaic) loss of the Y chromosome (mLOY), focusing on their underlying causes, pathophysiological significance, patterns of manifestation, and impact on disease progression in autoimmune, rheumatologic disorders. This research seeks to bridge existing knowledge gaps by exploring how such mutations influence immune homeostasis, cellular function, and susceptibility to inflammation-driven pathologies.\n\nThrough the integration of advanced immunological profiling, the study aspires to uncover key mechanisms that drive the initiation, progression, and complications of autoimmune rheumatic diseases. These analyses will combine single nucleotide polymorphisms (SNP) arrays, multiplex assays, transcriptomics, and flow cytometry staining of peripheral blood mononuclear cells to delineate the interplay between hematopoietic mutations and immune dysregulation.\n\nA further objective is the development of a multimodal framework for disease-specific characterization, enabling precise mapping of mutation-driven phenotypes across diverse autoimmune conditions. This framework will incorporate clinical, molecular, and imaging data.\n\nAdditionally, the AYLo study aims to explore the potential role of mLOY and other hematopoietic mutations as biomarkers for disease stratification, prognosis, and therapeutic response. The findings may open avenues for personalized treatment approaches, leveraging the molecular insights to inform targeted interventions and improve patient outcomes in autoimmune rheumatic disorders.\n\nBy integrating translational and basic science approaches, this study has the potential to redefine current paradigms in autoimmune disease research and therapy.",[575,576,577,90,578,579,580,581,28,582,583,584,303],"Giant Cell Arteritis (GCA)","Polymyalgia Rheumatica (PMR)","ANCA Associated Vasculitis (AAV)","IgG4-Related Diseases","Rheumatoid Arthritis (RA)","Psoriatic Arthritis (PsA)","Connective Tissue Disease","Interstitial Lung Disease Due to Systemic Disease (Disorder)","Interstitial Lung Disease (ILD)","Asthma Bronchiale",[586,587,588,267,270,86,90,578,91,262,581,28,454],"Autoimmune Diseases","Vasculitis","Large Vessel Vasculitis","2025-04-07",{"date":552,"type":36},{"date":592,"type":36},"2024-11-15",{"date":594,"type":21},"2026-07",{"name":596,"class":43},"University of Bonn",{"id":598,"slug":599,"hasResults":11,"nctId":600,"briefTitle":601,"officialTitle":602,"acronym":4,"eligibilityCriteria":603,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":604,"enrollmentInfo":605,"targetDuration":4,"studyType":22,"phases":607,"briefSummary":608,"conditions":609,"keywords":612,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":615,"lastUpdatePostDateStruct":616,"startDateStruct":618,"completionDateStruct":620,"leadSponsor":622,"locationsCount":73},"100581307","comparison-of-the-effects-of-yoga-and-conventional-physiotherapy-programs-in-sarcoidosis-100581307","NCT06848608","Comparison of the Effects of Yoga and Conventional Physiotherapy Programs in Sarcoidosis","Comparison of the Effects of Yoga and Conventional Physiotherapy Programs on Fatigue, Pulmonary Functions and Exercise Capacity in Patients With Sarcoidosis","Inclusion Criteria:\n\n* Being diagnosed with Sarcoidosis by a physician (Stage II-III-IV)\n* Pulmonary involvement\n* Having fatigue symptoms (FAS ≥22 points)\n* No immunosuppressive drug use for the last 1 year\n* No antidepressant use for the last 6 months\n\nExclusion Criteria:\n\n* Presence of cognitive impairment that prevents communication\n* Anemia\n* Uveitis\n* Diabetes\n* Pregnancy\n* Major cardiovascular diseases\n* Fractures\n* Osteoporosis\n* Those who have a neurological or orthopedic disease that will affect the treatment\n* Those who are in the exacerbation period of the disease\n* Tumor","75 Years",{"count":606,"type":21},32,[159],"Sarcoidosis is a multisystem disease, characterized by the formation of immune granulomas with various clinical symptoms depending on the involved organs, which can involve many organs and systems associated with emotional and physical consequences that affect the quality of life, whose cause is unknown, but usually affects the respiratory system, and occurs mostly in young and middle-aged adults. Lung involvement, seen in 95% of patients, causes limitation of lung capacity and decrease in inspiratory muscle strength, which are important factors that lead to an increase in dyspnea and a decrease in walking distance. In addition to respiratory muscle weakness, skeletal muscle dysfunction is also frequently observed. The most common symptoms in sarcoidosis are dyspnea and fatigue. When the current literature is examined, it can be seen that studies on non-pharmacological treatment methods in Sarcoidosis are quite limited. Although relatively common in Chronic Obstructive Pulmonary Disease (COPD), various studies conducted in patients with Bronchiectasis, Pulmonary Arterial Hypertension and Asthma have shown that yoga results in a decrease in dyspnea and fatigue, and an increase in pulmonary functions and exercise capacity. On the other hand, no study has been found on yogic techniques in Sarcoidosis. Aim of this study is to investigate the effects of yogic techniques and conventional physiotherapy program on pulmonary functions, body oxygen level test (BOLT), exercise capacity (6MWT), anxiety, depression, fatigue, dyspnea perception, sleep quality, and quality of life in sarcoidosis cases at different stages. In these patients known to have multisystem involvement, holistic approaches gain importance due to the nature of the disease.",[28,610,611],"Pulmonary Rehabilitation","Yoga",[613,236,614],"pulmonary rehabilitation","yoga","2025-02-21",{"date":617,"type":36},"2025-02-27",{"date":619,"type":36},"2023-11-30",{"date":621,"type":21},"2025-05-30",{"name":623,"class":43},"Saglik Bilimleri Universitesi",{"id":625,"slug":626,"hasResults":11,"nctId":627,"briefTitle":628,"officialTitle":629,"acronym":4,"eligibilityCriteria":630,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":631,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":632,"conditions":633,"keywords":641,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":645,"lastUpdatePostDateStruct":646,"startDateStruct":648,"completionDateStruct":650,"leadSponsor":652,"locationsCount":73},"100562965","cardiovascular-multimodality-imaging-study-100562965","NCT06610019","Cardiovascular Multimodality Imaging Study","Risk Stratification of Ischemic and Non-ischemic Cardiomyopathies in Racial and Ethnic Minority Groups in the Bronx - Cardiovascular Multimodality Imaging Study","Inclusion Criteria:\n\n* Any adult patient (18 years or older) referred for a cardiovascular magnetic resonance (CMR) imaging study in the Montefiore Health System\n\nExclusion Criteria:\n\n* Any patient who does not meet above criteria",{"count":82,"type":21},"Determining the etiology of cardiomyopathy is of high clinical importance for optimal treatment strategy and prediction of prognosis. There is increased risk for cardiovascular disease and higher propensity for cardiovascular related mortality among Black and non-Hispanic White patients. Recently, advanced cardiac imaging has become a vital tool in diagnosis and risk stratification of cardiovascular disease. Very limited data is available on the prevalence and characteristics of different cardiovascular diseases in Hispanic and African American minority groups, therefore, studying different racial and ethnic minority groups in the Bronx population is an exceptionally valuable source to determine the prevalence of cardiomyopathies among minority groups along with study survival in this population. This study aims to determine the etiology of cardiovascular disease in a diverse patient population by utilizing various cardiovascular imaging modalities, with a focus on cardiac magnetic resonance (CMR) imaging and to develop risk stratification models by applying advanced cardiovascular imaging markers.",[634,126,345,635,636,637,28,638,639,640],"Non-ischemic Cardiomyopathy","Right Ventricular Arrhythmogenic Cardiomyopathy","Cardiac Amyloidosis","Anderson Fabry Disease","Cancer Therapy-related Cardiac Dysfunction","Ventricular Arrythmia","Heart Failure",[642,643,644],"Cardiovascular Mortalities","Cardiomagnetic Resonance (CMR) Imaging","Prospective","2025-02-12",{"date":647,"type":36},"2025-02-14",{"date":649,"type":36},"2023-05-01",{"date":651,"type":21},"2031-12",{"name":653,"class":43},"Montefiore Medical Center",{"id":655,"slug":656,"hasResults":11,"nctId":657,"briefTitle":658,"officialTitle":659,"acronym":660,"eligibilityCriteria":661,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":662,"targetDuration":4,"studyType":22,"phases":663,"briefSummary":664,"conditions":665,"keywords":666,"overallStatus":672,"whyStopped":4,"lastUpdateSubmitDate":673,"lastUpdatePostDateStruct":674,"startDateStruct":676,"completionDateStruct":678,"leadSponsor":679,"locationsCount":73},"100566419","phase-4-prednisolone-for-12-versus-6-months-to-treat-pulmonary-sarcoidosis-100566419","NCT06654934","Prednisolone for 12 Versus 6 Months to Treat Pulmonary Sarcoidosis","Prednisolone for 12 Versus 6 Months to Treat Pulmonary Sarcoidosis: a Randomized Trial","DURASARC","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Computed tomography of the chest consistent with a diagnosis of sarcoidosis of the lung\u002Fmediastinal lymph nodes\n* Diagnosis of sarcoidosis made on cytological or histological samples\n* Having significant symptoms requiring immunosuppressive treatment and\u002For having reduced lung function (defined as forced vital capacity or forced expiratory volume in one second (FEV1) less than 80% predicted) or an extrapulmonary manifestation of the disease requiring treatment with low-medium dose glucocorticoids\n* Onset of symptoms within two years of study entry\n\nExclusion Criteria:\n\n* Pregnant or lactating women\n* Subjects having any manifestation requiring high dose steroid treatment (this includes symptomatic neurosarcoidosis, life threatening cardiac sarcoidosis, vision threatening posterior uveitis or other forms of vision threatening ocular sarcoidosis)\n* Having absolute contraindication for prednisone (this includes untreated glaucoma, uncontrolled diabetes mellitus, untreated infections, untreated severe psychiatric disorders)\n* Unwilling to participate in the study\n* Having received glucocorticoids (prednisolone equivalent \\>15 mg\u002Fday) for more than three weeks in the preceding year",{"count":157,"type":21},[409],"In this study, the efficacy and safety of treating pulmonary sarcoidosis with 12 months vs. 6 months of prednisolone will be compared. The hypothesis is that longer treatment DURAtion would be more effective in preventing treatment failure or early relapse in SARCoidosis (DURASARC trial). The premise of this hypothesis is that even small doses of prednisolone given over longer periods can effectively suppress disease activity in sarcoidosis without a significant increase in adverse effects.",[28],[667,668,669,235,670,671],"granulomatous disease","interstitial lung disease","diffuse lung disease","steroid","ILD","NOT_YET_RECRUITING","2024-10-21",{"date":675,"type":36},"2024-10-23",{"date":677,"type":21},"2024-11",{"date":40,"type":21},{"name":680,"class":43},"Post Graduate Institute of Medical Education and Research, Chandigarh",{"id":682,"slug":683,"hasResults":11,"nctId":684,"briefTitle":685,"officialTitle":686,"acronym":4,"eligibilityCriteria":687,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":208,"enrollmentInfo":688,"targetDuration":4,"studyType":22,"phases":690,"briefSummary":691,"conditions":692,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":693,"lastUpdatePostDateStruct":694,"startDateStruct":696,"completionDateStruct":698,"leadSponsor":700,"locationsCount":73},"100496992","sarcoidosis-and-immune-cells-in-lung-lymph-nodes-and-blood-100496992","NCT05751447","Sarcoidosis and Immune Cells in Lung, Lymph Nodes and Blood","Studie Av Cellulära Uttryck I Lymfkörtlar, Lungsköljvätska Och Blod Vid Sarkoidos.","Inclusion Criteria:\n\n* Suspicion of sarcoidosis\n* Swedish speaking\n* Able to understand and approve of study protocol\n* No contraindications for planned interventions\n\nExclusion Criteria:\n\n* No suspicion of sarcoidosis\n* Not Swedish-speking\n* Not able to understand study protocol\n* Not approving of stydy protocol\n* Contraindications for planned interventions",{"count":689,"type":21},560,[159],"Background:\n\nSarcoidosis is an inflammatory disease, most commonly affecting the lungs and intrathoracic lymph nodes but can affect virtually any organ, sometimes manifesting as life threatening cardiac arrythmias. Some patients resolve spontaneously, whereas others get a chronic disease leading to for instance impaired lung function and cardiac failure. The most severe cases might need a transplantation.\n\nIn the lungs, activated T cells are accumulated leading to release of cytokines, especially TNF-alpha is regarded as crucial for disease progression. Some segments of the T cell receptor and specific genes (HLA types) are connected to a resolving disease. More detailed knowledge about mechanisms why some experience a chronic disease course and others resolve spontaneously without treatment is to a large extent lacking. There is no cure, and despite treatment with immunosuppressants (often corticosteroids and cytotoxic agents), many patients experience a deteriorating disease.\n\nAim:\n\n1. Find biomarkers to be able to early predict which patients will develop a more severe\u002F chronic disease course and thereby enabeling early intervention before irreversible damage.\n2. Predict which treatment is best for a specific patient, i.e. individualize treatment.\n3. Find targets for new potential therapies.\n\nMethods:\n\nThe majority of data is collected at investigations normally performed during diagnostic work-up for sarcoidosis. Most patients undergo a bronchoscopy with bronchoalveolar lavage (BAL) and some also lymph node punction through oesophagus with the help of ultrasound. The BAL fluid that remains after clinical analysis is used for research purpose. For patients undergoing lymph node punction, one extra punction is performed for research purpose. Extra blood samples are taken from all patients.\n\nThe samples will mostly be used for studying T cells with immunohistochemistry, flow cytometry including activity markers, subtypes and receptors, but also cytokines and other cells (for instance B cells, NK and NKT cells). The patients are followed longitudinally, minimum 2 years. Some patients will undergo a second bronchoscopy 6-12 months after the first. Results from the immunological investigations will be correlated to disease course, genetics and result of treatment.\n\nSignificance :\n\nBy comparing the inflammation in several compartments (lung, lymph node , blood) at a molecular level with clinical disease course, genotype, and treatment response we hope to find biomarkers that can predict disease course and response to therapy. Thereby, we hope to be able to tailor therapy for each individual patient. By studying several compartments, the results may also help to improve understanding of how a systemic inflammation is distributed within the body, and thus also contribute to understanding of other inflammatory diseases.",[28],"2024-10-02",{"date":695,"type":36},"2024-10-04",{"date":697,"type":36},"2019-10-01",{"date":699,"type":21},"2034-05-01",{"name":220,"class":221},{"id":702,"slug":703,"hasResults":11,"nctId":704,"briefTitle":705,"officialTitle":706,"acronym":707,"eligibilityCriteria":708,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":709,"enrollmentInfo":710,"targetDuration":4,"studyType":22,"phases":712,"briefSummary":714,"conditions":715,"keywords":4,"overallStatus":672,"whyStopped":4,"lastUpdateSubmitDate":717,"lastUpdatePostDateStruct":718,"startDateStruct":720,"completionDateStruct":722,"leadSponsor":724,"locationsCount":4},"100474483","phase-2-sirolimus-in-cutaneous-sarcoidosis-100474483","NCT05458492","Sirolimus in Cutaneous Sarcoidosis","Cutaneous Sarcoidosis With Moderate to Severe Involvement of the Face : Multicenter Open-label Study of Oral Sirolimus Efficacy and Tolerance","SIRIUS","Inclusion Criteria:\n\n* Age ≥ 18 years old \\\u003C75 years old (men and women)\n* Cutaneous sarcoidosis of the face (diagnosed according to the following criteria : compatible clinical appearance showing erythemato-purple, brownish or yellowish macules or papules or nodules and compatible histological appearance with a facial or extra facial skin biopsy confirming the diagnosis of sarcoidosis showing epithelioid and giganto-cellular granuloma without caseous necrosis) moderate to severe defined by: \"Facial SASI\" Score (Sarcoidosis Area and Severity Index) ≥ 2 and PGA (Physician's Global Assessment,0 to 10 scale) ≥ 5\n* Health insurance plan coverage\n* Patients who never had a systemic treatment or who had at least one classical systemic treatment failure for sarcoidosis treatment\n* For women of childbearing age (unless post-menopausal or sterile), pregnancy test with βHCG negative. Effective contraception should be used during sirolimus treatment and for 12 weeks after stopping sirolimus\n* Patients who have signed a written consent\n\nExclusion Criteria:\n\n* Severe hepatic failure (Cytolysis (ALAT)\\> 3N and \u002F or Cholestase (PAL)\\> 3N)\n* Allergy or intolerance to sirolimus or at one of its excipients\n* Allergy to peanut or soybeans\n* Patient with a pulmonary or hepatic graft\n* General corticotherapy or immunosuppressive treatment (methotrexate, azathioprine, mycophenolate mofetil, cyclophosphamide, ciclosporin) in the month before the inclusion\n* Intra-lesional corticotherapy for less than 3 months\n* Biotherapy (anti-TNFa, anti-IL12\u002F23, anti-IL17A) within 3 months preceding the inclusion\n* Thalidomide or other -imide treatment for less than 3 months\n* Cyclins treatment for less than 1 month\n* Topical corticosteroids or topical tacrolimus for less than 1 week\n* Sarcoidosis involvement of at least one organ requiring systemic treatment other than sirolimus (oral corticosteroid or systemic immunosuppressive treatment)\n* Cholesterolemia\\> 300 mg\u002F dl or triglyceridemia\\> 400 mg\u002Fdl\n* Administration of strong CYP3A4 inhibitors or inducers such as rifampicin, ketoconazole, voriconazole, telithromycin , diltiazem, verapamil, erythromycin, clarythromycin, ciclosporin\n* Pregnancy or breastfeeding\n* Active infection including tuberculosis disease\n* Non-controlled arterial hypertension (TAS\\> 150 mmHg and \u002F or TAD\\> 100 mmHg)\n* Patient under guardianship or curatorship, patients deprived of freedom, under safeguarding of justice, receiving psychiatric care, under the constraint, admitted in a health or social institution for purposes other than those of research\n* Patient with cancer (except cutaneous basal cell carcinoma or in situ cervical cancer)\n* Risk of patient bad compliance\n* Grapefruit or grapefruit juice consumption during the treatment duration\n* Patients with fructose intolerance, galactose intolerance, glucose-galactose malabsorption, insufficiency in sucrase-isomaltase or Lapp lactase","74 Years",{"count":711,"type":21},10,[713],"PHASE2","Sarcoidosis is a multisystemic disease of unknown etiology characterized by the presence of epithelioid granulomas without caseous necrosis in the organs involved. Sarcoidosis cutaneous lesions can be severe. There is no recommendation for the treatment of cutaneous sarcoidosis. A recent study highlights the potential efficacy of mTOR inhibitors in the treatment of sarcoidosis granulomas. The hypothesis is that sirolimus could be effective for sarcoidosis treatment, especially for cutaneous lesions.\n\nThe main objective of this study is to evaluate sirolimus efficacy on cutaneous sarcoidosis of the face.\n\nThe main evaluation criteria is the percentage of patients with a significant clinical response (relative decrease in \"facial SASI\" ≥ 25%) at week 16 of treatment.",[28,716],"Cutaneous Sarcoidosis","2022-07-12",{"date":719,"type":36},"2022-07-14",{"date":721,"type":21},"2022-07",{"date":723,"type":21},"2027-05",{"name":113,"class":43}]